• Biomarin Pharmaceutical Inc.: Oppenheimer upgrades to outperform from market perform with a target price of USD 98.
  • Block, Inc.: BMO Capital Markets upgrades to outperform from market perform and reduces the target price from USD 100 to USD 89.
  • Carrier Global Corporation: Wolfe Research upgrades to outperform from peerperform with a target price of USD 80.
  • Comfort Systems Usa, Inc.: Sidoti & Company LLC upgrades to buy from neutral with a target price raised from USD 533 to USD 552.
  • Conagra Brands, Inc.: Goldman Sachs downgrades to neutral from buy with a target price reduced from USD 33 to USD 26.
  • Crowdstrike Holdings, Inc.: Arete Research downgrades to neutral from buy with a target price reduced from USD 540 to USD 456.
  • Exelixis, Inc.: Wells Fargo downgrades to equalweight from overweight with a target price of USD 36.
  • Fortinet, Inc.: Arete Research downgrades to sell from neutral with a price target raised from USD 62 to USD 83.
  • Intra-Cellular Therapies, Inc.: Mizuho Securities downgrades to neutral from outperform with a target price reduced from USD 140 to USD 132.
  • Lucid Group, Inc.: Redburn Atlantic downgrades to sell from neutral with a target price reduced from USD 3.50 to USD 1.13.
  • Nordson Corporation: BNP Paribas Exane downgrades to neutral from outperform with a target price reduced from USD 254 to USD 219.
  • The Toro Company: Northland Securities upgrades to outperform from market perform with a target price of USD 100.
  • Wingstop Inc.: Guggenheim upgrades to buy from neutral with a target price of USD 280.
  • Alnylam Pharmaceuticals, Inc.: HC Wainwright & Co maintains its buy recommendation and raises the target price from USD 400 to USD 500.
  • Celanese Corporation: Alembic Global Advisors maintains a neutral recommendation with a price target reduced from USD 105 to USD 58.
  • Celsius Holdings, Inc.: Jefferies maintains its buy recommendation and raises the target price from USD 33 to USD 40.
  • Dun & Bradstreet Holdings, Inc.: Jefferies maintains its buy recommendation and reduces the target price from USD 15 to USD 11.
  • Globant S.a.: Scotiabank maintains its sector perform recommendation and reduces the target price from 220 to USD 170.
  • Sentinelone, Inc.: Arete Research maintains its buy recommendation and reduces the target price from USD 50 to USD 36.